Last 12 months
Inside the activity.
0 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2014 Filed Apr 29, 2014 21:38 UTC |
Dittrich Thomas J.W.VP, Finance & CAO
|
Tax withholdingCommon Stock | 255 | $111.41 | $28,409.55 |
DisclosureSEC source: 0001127602-14-015506 · form4.xml · nonDerivative · entry 4 Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,599 Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:42 UTC |
Harper Sean EEVP, Research & Development
|
Tax withholdingCommon Stock | 56 | $111.41 | $6,238.96 |
DisclosureSEC source: 0001127602-14-015507 · form4.xml · nonDerivative · entry 4 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,407 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 25,000 RSUs which fully vest on 12/31/2014; 2,040 RSUs which vest in one installment of 2,040 on 4/25/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 417 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:42 UTC |
Harper Sean EEVP, Research & Development
|
Tax withholdingCommon Stock | 1,490 | $111.41 | $166,000.90 |
DisclosureSEC source: 0001127602-14-015507 · form4.xml · nonDerivative · entry 3 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,463 Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:45 UTC |
HOOPER ANTHONY CEVP, Global Commercial Ops.
|
Tax withholdingCommon Stock | 56 | $111.41 | $6,238.96 |
DisclosureSEC source: 0001127602-14-015508 · form4.xml · nonDerivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,664 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 7,239 RSUs which vest in one installment on 3/2/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 417 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:45 UTC |
HOOPER ANTHONY CEVP, Global Commercial Ops.
|
Tax withholdingCommon Stock | 1,490 | $111.41 | $166,000.90 |
DisclosureSEC source: 0001127602-14-015508 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,720 Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:48 UTC |
Michael A KellyActing CFO
|
Tax withholdingCommon Stock | 6 | $111.41 | $668.46 |
DisclosureSEC source: 0001127602-14-015509 · form4.xml · nonDerivative · entry 5 Michael A Kelly · CIK 0001335311 · Acting CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,106 Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:48 UTC |
Michael A KellyActing CFO
|
Tax withholdingCommon Stock | 140 | $111.41 | $15,597.40 |
DisclosureSEC source: 0001127602-14-015509 · form4.xml · nonDerivative · entry 4 Michael A Kelly · CIK 0001335311 · Acting CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,112 Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:54 UTC | Tax withholdingCommon Stock | 28 | $111.41 | $3,119.48 |
DisclosureSEC source: 0001127602-14-015510 · form4.xml · nonDerivative · entry 4 MCNAMEE BRIAN M · CIK 0001183885 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,091 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 22,081 RSUs which fully vest on 12/31/2014; 2,550 RSUs which vest in one installment of 2,550 on 4/25/2015; 2,993 RSUs which vest in two annual installments of 1,474 and 1,519 on 4/27/2015 and 4/27/2016, respectively; 4,439 RSUs which vest in three installments of 1,464, 1,465 and 1,510 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively; 11,176 RSUs which vest in two equal installments of 3,688 each on 10/25/2014 and 10/25/2015 and one installment of 3,800 on 10/25/2016; and 4,707 RSUs which vest in two equal installments of 1,553 on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 342 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
|
| April 27, 2014 Filed Apr 29, 2014 21:54 UTC | Tax withholdingCommon Stock | 734 | $111.41 | $81,774.94 |
DisclosureSEC source: 0001127602-14-015510 · form4.xml · nonDerivative · entry 3 MCNAMEE BRIAN M · CIK 0001183885 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,119 Read SEC document |
|
| April 27, 2014 Filed Apr 29, 2014 21:56 UTC |
Patton Cynthia MSVP & CCO
|
Tax withholdingCommon Stock | 8 | $111.41 | $891.28 |
DisclosureSEC source: 0001127602-14-015511 · form4.xml · nonDerivative · entry 4 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,185 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,000 RSUs which fully vest on 10/28/2014; 508 RSUs which vest in on 4/25/2015; 804 RSUs which vest in two annual installments of 396 on 4/27/2015 and 408 on 4/27/2016; 5,420 RSUs which vest in three installments of 1,788, 1,789 and 1,843 on 10/26/2014, 10/26/2015 and 10/26/2016, respectively; 2,103 RSUs which vest in three installments of 693, 694 and 716 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively; and 1,092 RSUs which vest in two equal installments of 360 on 1/31/2016 and 1/31/2017 and one installment of 372 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 235 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:56 UTC |
Patton Cynthia MSVP & CCO
|
Tax withholdingCommon Stock | 182 | $111.41 | $20,276.62 |
DisclosureSEC source: 0001127602-14-015511 · form4.xml · nonDerivative · entry 3 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,193 Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:59 UTC |
Piacquad DavidSVP, Business Development
|
Tax withholdingCommon Stock | 10 | $111.41 | $1,114.10 |
DisclosureSEC source: 0001127602-14-015512 · form4.xml · nonDerivative · entry 4 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,604 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 3,750 RSUs which fully vest on 8/3/2014; 632 RSUs which fully vest on 4/25/2015; 1,005 RSUs which vest in 2 annual installments of 495 on 4/27/2015 and 510 on 4/27/2016; 840 RSUs which vest in 2 equal installments of 277 each on 4/26/2015 and 4/26/2016 and one installment of 286 on 4/26/2017; and 9,226 RSUs which vest in 2 equal installments of 4,163 each on 4/26/2015 and 4/26/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 221 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:59 UTC |
Piacquad DavidSVP, Business Development
|
Tax withholdingCommon Stock | 259 | $111.41 | $28,855.19 |
DisclosureSEC source: 0001127602-14-015512 · form4.xml · nonDerivative · entry 3 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,614 Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 22:03 UTC |
SCOTT DAVID JSVP, Gen. Counsel & Secy.
|
Tax withholdingCommon Stock | 38 | $111.41 | $4,233.58 |
DisclosureSEC source: 0001127602-14-015514 · form4.xml · nonDerivative · entry 4 SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,600 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 22,081 RSUs which fully vest on 12/31/2014; 3,808 RSUs which vest in one installment on 4/25/2015; 4,115 RSUs which vest in two annual installments of 2,027 and 2,088 on 4/27/2015 and 4/27/2016, respectively; 5,374 RSUs which vest in two equal installments of 1,773 each on 1/28/2015 and 1/28/2016 and one installment of 1,828 on 1/28/2017; and 3,362 RSUs which vest in two equal installments of 1,109 on 1/31/2016 and 1/31/2017 and one installment of 1,144 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 297 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 22:03 UTC |
SCOTT DAVID JSVP, Gen. Counsel & Secy.
|
Tax withholdingCommon Stock | 1,010 | $111.41 | $112,524.10 |
DisclosureSEC source: 0001127602-14-015514 · form4.xml · nonDerivative · entry 3 SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,638 Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 22:05 UTC |
Tross Stuart ASVP, Human Resources
|
Tax withholdingCommon Stock | 7 | $111.41 | $779.87 |
DisclosureSEC source: 0001127602-14-015515 · form4.xml · nonDerivative · entry 4 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,204 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 13,958 RSUs which fully vest on 9/1/2014; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; and 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 610 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 22:05 UTC |
Tross Stuart ASVP, Human Resources
|
Tax withholdingCommon Stock | 164 | $111.41 | $18,271.24 |
DisclosureSEC source: 0001127602-14-015515 · form4.xml · nonDerivative · entry 3 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,211 Read SEC document |
| April 26, 2014 Filed Apr 29, 2014 21:32 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 783 | $111.41 | $87,234.03 |
DisclosureSEC source: 0001127602-14-015501 · form4.xml · nonDerivative · entry 3 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,860 Read SEC document |
| April 26, 2014 Filed Apr 29, 2014 21:32 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 1,566 | $111.41 | $174,468.06 |
DisclosureSEC source: 0001127602-14-015501 · form4.xml · nonDerivative · entry 2 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,643 Read SEC document |
| April 26, 2014 Filed Apr 29, 2014 21:35 UTC |
Balachandran MadhavanEVP, Operations
|
Tax withholdingCommon Stock | 437 | $111.41 | $48,686.17 |
DisclosureSEC source: 0001127602-14-015503 · form4.xml · nonDerivative · entry 2 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,186 Read SEC document |
| April 26, 2014 Filed Apr 29, 2014 21:38 UTC |
Dittrich Thomas J.W.VP, Finance & CAO
|
Tax withholdingCommon Stock | 170 | $111.41 | $18,939.70 |
DisclosureSEC source: 0001127602-14-015506 · form4.xml · nonDerivative · entry 3 Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,854 Read SEC document |
| April 26, 2014 Filed Apr 29, 2014 21:42 UTC |
Harper Sean EEVP, Research & Development
|
Tax withholdingCommon Stock | 601 | $111.41 | $66,957.41 |
DisclosureSEC source: 0001127602-14-015507 · form4.xml · nonDerivative · entry 2 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,953 Read SEC document |
| April 26, 2014 Filed Apr 29, 2014 21:48 UTC |
Michael A KellyActing CFO
|
Tax withholdingCommon Stock | 116 | $111.41 | $12,923.56 |
DisclosureSEC source: 0001127602-14-015509 · form4.xml · nonDerivative · entry 3 Michael A Kelly · CIK 0001335311 · Acting CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,252 Read SEC document |
| April 26, 2014 Filed Apr 29, 2014 21:54 UTC | Tax withholdingCommon Stock | 723 | $111.41 | $80,549.43 |
DisclosureSEC source: 0001127602-14-015510 · form4.xml · nonDerivative · entry 2 MCNAMEE BRIAN M · CIK 0001183885 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,853 Read SEC document |
|
| April 26, 2014 Filed Apr 29, 2014 21:56 UTC |
Patton Cynthia MSVP & CCO
|
Tax withholdingCommon Stock | 50 | $111.41 | $5,570.50 |
DisclosureSEC source: 0001127602-14-015511 · form4.xml · nonDerivative · entry 2 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,375 Read SEC document |
| April 26, 2014 Filed Apr 29, 2014 22:03 UTC |
SCOTT DAVID JSVP, Gen. Counsel & Secy.
|
Tax withholdingCommon Stock | 723 | $111.41 | $80,549.43 |
DisclosureSEC source: 0001127602-14-015514 · form4.xml · nonDerivative · entry 2 SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,648 Read SEC document |
| April 26, 2014 Filed Apr 29, 2014 22:05 UTC |
Tross Stuart ASVP, Human Resources
|
Tax withholdingCommon Stock | 137 | $111.41 | $15,263.17 |
DisclosureSEC source: 0001127602-14-015515 · form4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,375 Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 20:58 UTC |
BALTIMORE DAVIDDirector
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015481 · form4.xml · nonDerivative · entry 1 BALTIMORE DAVID · CIK 0001185858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,159 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:00 UTC |
BIONDI FRANKDirector
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015482 · form4.xml · nonDerivative · entry 1 BIONDI FRANK · CIK 0001032669 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,814 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 591 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:04 UTC |
COFFMAN VANCE DDirector
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015483 · form4.xml · nonDerivative · entry 1 COFFMAN VANCE D · CIK 0001193998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,580 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 356 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:06 UTC |
ECKERT ROBERTDirector
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015484 · form4.xml · nonDerivative · entry 1 ECKERT ROBERT · CIK 0001194256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,674 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 34 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:09 UTC |
Garland Greg C.Director
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015485 · form4.xml · nonDerivative · entry 1 Garland Greg C. · CIK 0001503107 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,224 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested imediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:12 UTC |
de Carbonnel FrancoisDirector
|
Tax withholdingCommon Stock | 539 | $113.72 | $61,295.08 |
DisclosureSEC source: 0001127602-14-015487 · form4.xml · nonDerivative · entry 2 de Carbonnel Francois · CIK 0001447121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,590 F2 · balance_after: These shares include 105 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:12 UTC |
de Carbonnel FrancoisDirector
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015487 · form4.xml · nonDerivative · entry 1 de Carbonnel Francois · CIK 0001447121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,148 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:14 UTC |
HENDERSON REBECCA MDirector
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015488 · form4.xml · nonDerivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,372 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 193 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:16 UTC |
HERRINGER FRANK CDirector
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015490 · form4.xml · nonDerivative · entry 1 HERRINGER FRANK C · CIK 0001171694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,230 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 662 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:18 UTC |
Jacks TylerDirector
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015492 · form4.xml · nonDerivative · entry 1 Jacks Tyler · CIK 0001464237 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:20 UTC |
OMENN GILBERT SDirector
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015495 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,547 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 232 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:22 UTC |
PELHAM JUDITH CDirector
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015497 · form4.xml · nonDerivative · entry 1 PELHAM JUDITH C · CIK 0001185287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,734 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's Common Stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:24 UTC |
SUGAR RONALD DDirector
|
GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015498 · form4.xml · nonDerivative · entry 1 SUGAR RONALD D · CIK 0001216519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,017 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 154 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:32 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 3,617 | $113.72 | $411,325.24 |
DisclosureSEC source: 0001127602-14-015501 · form4.xml · nonDerivative · entry 1 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,209 Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:35 UTC |
Balachandran MadhavanEVP, Operations
|
Tax withholdingCommon Stock | 740 | $113.72 | $84,152.80 |
DisclosureSEC source: 0001127602-14-015503 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,623 Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:38 UTC |
Dittrich Thomas J.W.VP, Finance & CAO
|
GrantCommon Stock | 681 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015506 · form4.xml · nonDerivative · entry 2 Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,024 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/25/2016, 4/25/2017 and 4/25/2018, respectively. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:38 UTC |
Dittrich Thomas J.W.VP, Finance & CAO
|
Tax withholdingCommon Stock | 312 | $113.72 | $35,480.64 |
DisclosureSEC source: 0001127602-14-015506 · form4.xml · nonDerivative · entry 1 Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,343 Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:42 UTC |
Harper Sean EEVP, Research & Development
|
Tax withholdingCommon Stock | 1,034 | $113.72 | $117,586.48 |
DisclosureSEC source: 0001127602-14-015507 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,554 Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:48 UTC |
Michael A KellyActing CFO
|
GrantCommon Stock | 628 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015509 · form4.xml · nonDerivative · entry 2 Michael A Kelly · CIK 0001335311 · Acting CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,368 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/25/2016, 4/25/2017 and 4/25/2017. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:48 UTC |
Michael A KellyActing CFO
|
Tax withholdingCommon Stock | 174 | $113.72 | $19,787.28 |
DisclosureSEC source: 0001127602-14-015509 · form4.xml · nonDerivative · entry 1 Michael A Kelly · CIK 0001335311 · Acting CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,740 Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:54 UTC | Tax withholdingCommon Stock | 1,234 | $113.72 | $140,330.48 |
DisclosureSEC source: 0001127602-14-015510 · form4.xml · nonDerivative · entry 1 MCNAMEE BRIAN M · CIK 0001183885 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,576 Read SEC document |
|
| April 25, 2014 Filed Apr 29, 2014 21:56 UTC |
Patton Cynthia MSVP & CCO
|
Tax withholdingCommon Stock | 186 | $113.72 | $21,151.92 |
DisclosureSEC source: 0001127602-14-015511 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,425 Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:59 UTC |
Piacquad DavidSVP, Business Development
|
GrantCommon Stock | 1,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015512 · form4.xml · nonDerivative · entry 2 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,873 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 4/25/2016, 4/25/2017 and 4/25/2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.